BioSpace News Archive

CureVac N.V. (Nasdaq:CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive interim data from the ongoing Phase 2 study assessing monovalent and bivalent modified vaccine candidates against COVID-19.

Axial Therapeutics announced that A. Stewart Campbell, PhD, Chief Executive Officer, will participate in the following upcoming conferences.

Compass Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported a business update.

Spero Therapeutics, Inc. today provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024.

Soleno Therapeutics, Inc. today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to three new employees.

Lifecore Biomedical, Inc. announced that it has finalized a series of updated commercial arrangements with its long-term commercial Hyaluronic Acid and CDMO customer, Alcon to extend and expand the existing CDMO relationship.

Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share.

Akeso (9926.HK) announced the China National Medical Products Administration (NMPA) has accepted the supplemental new drug application (sNDA) of cadonilimab (开坦尼®, PD-1/CTLA-4 bispecific antibody, AK104) in combination with capecitabine plus oxaliplatin (XELOX) for first-line treatment of unresectable locally advanced, recurrent or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Cerapedics Inc. today announced that Valeska Schroeder , Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

ProfoundBio today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan (Rina-S; PRO1184).